Portal-systemic encephalopathy, also known as hepatic encephalopathy, is a neurological disorder resulting from liver dysfunction or liver disease. It is characterized by a range of neuropsychiatric abnormalities that arise from the accumulation of toxins in the bloodstream, usually removed by the liver.
The condition typically arises when the liver cannot adequately detoxify substances, leading to their accumulation and subsequent impact on brain function. The elevated levels of toxins in the bloodstream, particularly ammonia, can lead to alterations in brain function and the development of portal-systemic encephalopathy.
The exact mechanisms underlying the neurological changes are complex and must be thoroughly understood. However, toxins are believed to disrupt the normal functioning of brain cells and neurotransmitter systems, leading to the characteristic symptoms of encephalopathy.
Epidemiology
The prevalence is closely linked to the prevalence of underlying liver conditions, particularly cirrhosis. PSE is estimated to occur in approximately 30-45% of patients with cirrhosis. The overall prevalence of in the general population is challenging due to liver disease etiology and diagnostic criteria variations. It does not appear to have a significant gender or racial predilection.
It can affect individuals of any gender or race. The occurrence is more closely associated with the underlying liver condition, regardless of gender or race. The prevalence may vary in different regions based on the prevalence of underlying liver diseases and risk factors specific to those populations. Regions with a higher burden of chronic hepatitis B or C infections, alcoholic liver disease, or certain genetic liver disorders may have a higher prevalence of PSE.
Anatomy
Pathophysiology
One of the central mechanisms of PSE is the buildup of ammonia in the blood and brain. Normally, the liver plays a crucial role in removing ammonia, a waste product of protein metabolism. In liver dysfunction, notably cirrhosis, ammonia is not effectively metabolized, leading to increased levels in the bloodstream. In PSE, the elevated levels of ammonia and other toxins in the blood can cross the blood-brain barrier more readily due to its increased permeability.
This allows these substances to affect brain cells and neurotransmitter systems directly. Ammonia and other toxins disrupt the brain’s normal functioning of neurotransmitter systems. One key effect is the alteration of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter. Increased ammonia levels inhibit GABA synthesis, leading to reduced inhibitory control and increased excitability of neurons. Astrocytes, a type of brain cell, play a vital role in maintaining brain homeostasis and detoxifying ammonia.
In PSE, astrocytes become dysfunctional due to ammonia toxicity and energy depletion. This further impairs ammonia detoxification and contributes to the pathogenesis of encephalopathy. Liver dysfunction and associated portal hypertension can lead to systemic inflammation and oxidative stress. These processes contribute to the progression of PSE by further disrupting neuronal function and exacerbating brain injury. The gut microbiota, which refers to the microbial communities in the intestines, also plays a role in PSE.
Dysbiosis, an imbalance in gut microbial composition, can increase the production of toxic substances such as ammonia and short-chain fatty acids. These compounds can reach the bloodstream and contribute to the development and progression of encephalopathy. The cumulative effect of these pathophysiological factors leads to the characteristic neuropsychiatric symptoms seen in PSE, including cognitive impairment, personality changes, motor abnormalities, and altered consciousness.
Etiology
Portosystemic shunts are abnormal connections between the portal vein and systemic veins. These shunts can be congenital, diverting blood flow from the liver and reducing the liver’s ability to detoxify substances. The diversion of blood-containing toxins contributes to the development of PSE. PSE can also occur in cases of acute liver failure, a rapid and severe deterioration of liver function.
Acute liver failure can be caused by various factors, including viral hepatitis, drug-induced liver injury, autoimmune hepatitis, Wilson’s disease, and certain medications or toxins. The rapid onset of liver dysfunction in acute liver failure can lead to the development of PSE. Cirrhosis is the most common underlying cause of PSE.
It refers to advanced liver scarring and damage resulting from various liver diseases such as chronic hepatitis B or C infection, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), autoimmune liver diseases, and others. Cirrhosis disrupts normal liver function, impairs blood flow through the liver, and accumulates toxins in the bloodstream, contributing to PSE development.
Genetics
Prognostic Factors
The prognosis is closely tied to the underlying liver condition contributing to its development. If the underlying liver disease is progressive and irreversible, such as advanced cirrhosis, the prognosis for PSE may be less favorable. In contrast, addressing the primary liver condition can improve the prognosis if the underlying liver disease is treatable or reversible.
Clinical History
Clinical History
Patients may have a history of underlying liver disease or symptoms related to liver dysfunction. This can include fatigue, jaundice, abdominal pain or discomfort, hepatomegaly, or ascites. A range of neuropsychiatric symptoms characterizes PSE. Patients may report changes in behavior, personality, cognition, and mood. They may experience confusion, disorientation, memory problems, difficulty concentrating, and alterations in sleep patterns.
Patients may exhibit motor abnormalities such as tremors, abnormal movements, or even coma in more severe cases. Patients may describe episodes of acute neurological deterioration, known as encephalopathy episodes. Various factors, such as infections, gastrointestinal bleeding, certain medications, dietary factors, or electrolyte imbalances, can trigger these episodes. The frequency, severity, and triggers of these episodes should be assessed.
The patient’s current and past medications should be reviewed, as certain medications can worsen or precipitate encephalopathy. Additionally, the patient’s dietary habits, particularly protein intake, should be assessed, as dietary protein can influence ammonia levels and encephalopathy severity. In some cases, a family history of liver disease or metabolic disorders may contribute to PSE. Gathering information about family members with similar conditions or neurological symptoms can provide valuable insights.
Physical Examination
Physical Examination
The patient may exhibit varying confusion, disorientation, or impaired consciousness. In severe cases, they may be unresponsive or in a comatose state. Patients may demonstrate tremors, asterixis (flapping tremor of the hands), or other involuntary movements.
Increased muscle tone or rigidity may be observed, particularly in more advanced stages of encephalopathy. Patients may have difficulty with coordination and exhibit unsteady or ataxic gait.
A distinctive musty, sweet, or slightly fecal odor of the breath is associated with liver disease. Patients may exhibit signs of malnutrition, such as muscle wasting or loss of subcutaneous fat.
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Differential Diagnoses
Meningitis
Hypoglycemia
Anoxia
Wernicke encephalopathy
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
Patients who experience upper gastrointestinal bleeding are at significant risk of developing hepatic encephalopathy. However, this risk can be reduced through gastrointestinal lavage using mannitol or non-absorbable disaccharides, which help decrease the likelihood of overt HE. Treating the underlying cirrhosis in a way that slows down or reverses its progression can also serve as primary prophylaxis for HE.
This can involve interventions such as alcohol abstinence for individuals with alcohol misuse, antiviral medications for virus-related cirrhosis, and appropriate nutrition for malnourished patients, addressing both excess and deficiency and iron overload, among other factors. For patients who have experienced episodes of hepatic encephalopathy and are at a higher risk of recurrence, using lactulose can reduce the risk of another episode by 50%. In cases where lactulose is not well-tolerated, rifaximin, a non-absorbable antibiotic, can be used as an alternative.
A combination of lactulose and rifaximin for patients with recurrent episodes can further decrease the risk of subsequent episodes. In cases where patients are severely debilitated due to their condition, the goal is to identify and close off the shunt causing the encephalopathy. Patients at an increased risk of aspiration or respiratory compromise should be closely monitored and may require prophylactic intubation, with intensive care unit admission as necessary.
Portal-systemic encephalopathy, also known as hepatic encephalopathy, is a neurological disorder resulting from liver dysfunction or liver disease. It is characterized by a range of neuropsychiatric abnormalities that arise from the accumulation of toxins in the bloodstream, usually removed by the liver.
The condition typically arises when the liver cannot adequately detoxify substances, leading to their accumulation and subsequent impact on brain function. The elevated levels of toxins in the bloodstream, particularly ammonia, can lead to alterations in brain function and the development of portal-systemic encephalopathy.
The exact mechanisms underlying the neurological changes are complex and must be thoroughly understood. However, toxins are believed to disrupt the normal functioning of brain cells and neurotransmitter systems, leading to the characteristic symptoms of encephalopathy.
The prevalence is closely linked to the prevalence of underlying liver conditions, particularly cirrhosis. PSE is estimated to occur in approximately 30-45% of patients with cirrhosis. The overall prevalence of in the general population is challenging due to liver disease etiology and diagnostic criteria variations. It does not appear to have a significant gender or racial predilection.
It can affect individuals of any gender or race. The occurrence is more closely associated with the underlying liver condition, regardless of gender or race. The prevalence may vary in different regions based on the prevalence of underlying liver diseases and risk factors specific to those populations. Regions with a higher burden of chronic hepatitis B or C infections, alcoholic liver disease, or certain genetic liver disorders may have a higher prevalence of PSE.
One of the central mechanisms of PSE is the buildup of ammonia in the blood and brain. Normally, the liver plays a crucial role in removing ammonia, a waste product of protein metabolism. In liver dysfunction, notably cirrhosis, ammonia is not effectively metabolized, leading to increased levels in the bloodstream. In PSE, the elevated levels of ammonia and other toxins in the blood can cross the blood-brain barrier more readily due to its increased permeability.
This allows these substances to affect brain cells and neurotransmitter systems directly. Ammonia and other toxins disrupt the brain’s normal functioning of neurotransmitter systems. One key effect is the alteration of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter. Increased ammonia levels inhibit GABA synthesis, leading to reduced inhibitory control and increased excitability of neurons. Astrocytes, a type of brain cell, play a vital role in maintaining brain homeostasis and detoxifying ammonia.
In PSE, astrocytes become dysfunctional due to ammonia toxicity and energy depletion. This further impairs ammonia detoxification and contributes to the pathogenesis of encephalopathy. Liver dysfunction and associated portal hypertension can lead to systemic inflammation and oxidative stress. These processes contribute to the progression of PSE by further disrupting neuronal function and exacerbating brain injury. The gut microbiota, which refers to the microbial communities in the intestines, also plays a role in PSE.
Dysbiosis, an imbalance in gut microbial composition, can increase the production of toxic substances such as ammonia and short-chain fatty acids. These compounds can reach the bloodstream and contribute to the development and progression of encephalopathy. The cumulative effect of these pathophysiological factors leads to the characteristic neuropsychiatric symptoms seen in PSE, including cognitive impairment, personality changes, motor abnormalities, and altered consciousness.
Portosystemic shunts are abnormal connections between the portal vein and systemic veins. These shunts can be congenital, diverting blood flow from the liver and reducing the liver’s ability to detoxify substances. The diversion of blood-containing toxins contributes to the development of PSE. PSE can also occur in cases of acute liver failure, a rapid and severe deterioration of liver function.
Acute liver failure can be caused by various factors, including viral hepatitis, drug-induced liver injury, autoimmune hepatitis, Wilson’s disease, and certain medications or toxins. The rapid onset of liver dysfunction in acute liver failure can lead to the development of PSE. Cirrhosis is the most common underlying cause of PSE.
It refers to advanced liver scarring and damage resulting from various liver diseases such as chronic hepatitis B or C infection, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), autoimmune liver diseases, and others. Cirrhosis disrupts normal liver function, impairs blood flow through the liver, and accumulates toxins in the bloodstream, contributing to PSE development.
The prognosis is closely tied to the underlying liver condition contributing to its development. If the underlying liver disease is progressive and irreversible, such as advanced cirrhosis, the prognosis for PSE may be less favorable. In contrast, addressing the primary liver condition can improve the prognosis if the underlying liver disease is treatable or reversible.
Clinical History
Patients may have a history of underlying liver disease or symptoms related to liver dysfunction. This can include fatigue, jaundice, abdominal pain or discomfort, hepatomegaly, or ascites. A range of neuropsychiatric symptoms characterizes PSE. Patients may report changes in behavior, personality, cognition, and mood. They may experience confusion, disorientation, memory problems, difficulty concentrating, and alterations in sleep patterns.
Patients may exhibit motor abnormalities such as tremors, abnormal movements, or even coma in more severe cases. Patients may describe episodes of acute neurological deterioration, known as encephalopathy episodes. Various factors, such as infections, gastrointestinal bleeding, certain medications, dietary factors, or electrolyte imbalances, can trigger these episodes. The frequency, severity, and triggers of these episodes should be assessed.
The patient’s current and past medications should be reviewed, as certain medications can worsen or precipitate encephalopathy. Additionally, the patient’s dietary habits, particularly protein intake, should be assessed, as dietary protein can influence ammonia levels and encephalopathy severity. In some cases, a family history of liver disease or metabolic disorders may contribute to PSE. Gathering information about family members with similar conditions or neurological symptoms can provide valuable insights.
Physical Examination
The patient may exhibit varying confusion, disorientation, or impaired consciousness. In severe cases, they may be unresponsive or in a comatose state. Patients may demonstrate tremors, asterixis (flapping tremor of the hands), or other involuntary movements.
Increased muscle tone or rigidity may be observed, particularly in more advanced stages of encephalopathy. Patients may have difficulty with coordination and exhibit unsteady or ataxic gait.
A distinctive musty, sweet, or slightly fecal odor of the breath is associated with liver disease. Patients may exhibit signs of malnutrition, such as muscle wasting or loss of subcutaneous fat.
Differential Diagnoses
Meningitis
Hypoglycemia
Anoxia
Wernicke encephalopathy
Patients who experience upper gastrointestinal bleeding are at significant risk of developing hepatic encephalopathy. However, this risk can be reduced through gastrointestinal lavage using mannitol or non-absorbable disaccharides, which help decrease the likelihood of overt HE. Treating the underlying cirrhosis in a way that slows down or reverses its progression can also serve as primary prophylaxis for HE.
This can involve interventions such as alcohol abstinence for individuals with alcohol misuse, antiviral medications for virus-related cirrhosis, and appropriate nutrition for malnourished patients, addressing both excess and deficiency and iron overload, among other factors. For patients who have experienced episodes of hepatic encephalopathy and are at a higher risk of recurrence, using lactulose can reduce the risk of another episode by 50%. In cases where lactulose is not well-tolerated, rifaximin, a non-absorbable antibiotic, can be used as an alternative.
A combination of lactulose and rifaximin for patients with recurrent episodes can further decrease the risk of subsequent episodes. In cases where patients are severely debilitated due to their condition, the goal is to identify and close off the shunt causing the encephalopathy. Patients at an increased risk of aspiration or respiratory compromise should be closely monitored and may require prophylactic intubation, with intensive care unit admission as necessary.
medtigo
Portal-Systemic Encephalopathy
Updated :
June 5, 2024
Portal-systemic encephalopathy, also known as hepatic encephalopathy, is a neurological disorder resulting from liver dysfunction or liver disease. It is characterized by a range of neuropsychiatric abnormalities that arise from the accumulation of toxins in the bloodstream, usually removed by the liver.
The condition typically arises when the liver cannot adequately detoxify substances, leading to their accumulation and subsequent impact on brain function. The elevated levels of toxins in the bloodstream, particularly ammonia, can lead to alterations in brain function and the development of portal-systemic encephalopathy.
The exact mechanisms underlying the neurological changes are complex and must be thoroughly understood. However, toxins are believed to disrupt the normal functioning of brain cells and neurotransmitter systems, leading to the characteristic symptoms of encephalopathy.
The prevalence is closely linked to the prevalence of underlying liver conditions, particularly cirrhosis. PSE is estimated to occur in approximately 30-45% of patients with cirrhosis. The overall prevalence of in the general population is challenging due to liver disease etiology and diagnostic criteria variations. It does not appear to have a significant gender or racial predilection.
It can affect individuals of any gender or race. The occurrence is more closely associated with the underlying liver condition, regardless of gender or race. The prevalence may vary in different regions based on the prevalence of underlying liver diseases and risk factors specific to those populations. Regions with a higher burden of chronic hepatitis B or C infections, alcoholic liver disease, or certain genetic liver disorders may have a higher prevalence of PSE.
One of the central mechanisms of PSE is the buildup of ammonia in the blood and brain. Normally, the liver plays a crucial role in removing ammonia, a waste product of protein metabolism. In liver dysfunction, notably cirrhosis, ammonia is not effectively metabolized, leading to increased levels in the bloodstream. In PSE, the elevated levels of ammonia and other toxins in the blood can cross the blood-brain barrier more readily due to its increased permeability.
This allows these substances to affect brain cells and neurotransmitter systems directly. Ammonia and other toxins disrupt the brain’s normal functioning of neurotransmitter systems. One key effect is the alteration of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter. Increased ammonia levels inhibit GABA synthesis, leading to reduced inhibitory control and increased excitability of neurons. Astrocytes, a type of brain cell, play a vital role in maintaining brain homeostasis and detoxifying ammonia.
In PSE, astrocytes become dysfunctional due to ammonia toxicity and energy depletion. This further impairs ammonia detoxification and contributes to the pathogenesis of encephalopathy. Liver dysfunction and associated portal hypertension can lead to systemic inflammation and oxidative stress. These processes contribute to the progression of PSE by further disrupting neuronal function and exacerbating brain injury. The gut microbiota, which refers to the microbial communities in the intestines, also plays a role in PSE.
Dysbiosis, an imbalance in gut microbial composition, can increase the production of toxic substances such as ammonia and short-chain fatty acids. These compounds can reach the bloodstream and contribute to the development and progression of encephalopathy. The cumulative effect of these pathophysiological factors leads to the characteristic neuropsychiatric symptoms seen in PSE, including cognitive impairment, personality changes, motor abnormalities, and altered consciousness.
Portosystemic shunts are abnormal connections between the portal vein and systemic veins. These shunts can be congenital, diverting blood flow from the liver and reducing the liver’s ability to detoxify substances. The diversion of blood-containing toxins contributes to the development of PSE. PSE can also occur in cases of acute liver failure, a rapid and severe deterioration of liver function.
Acute liver failure can be caused by various factors, including viral hepatitis, drug-induced liver injury, autoimmune hepatitis, Wilson’s disease, and certain medications or toxins. The rapid onset of liver dysfunction in acute liver failure can lead to the development of PSE. Cirrhosis is the most common underlying cause of PSE.
It refers to advanced liver scarring and damage resulting from various liver diseases such as chronic hepatitis B or C infection, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), autoimmune liver diseases, and others. Cirrhosis disrupts normal liver function, impairs blood flow through the liver, and accumulates toxins in the bloodstream, contributing to PSE development.
The prognosis is closely tied to the underlying liver condition contributing to its development. If the underlying liver disease is progressive and irreversible, such as advanced cirrhosis, the prognosis for PSE may be less favorable. In contrast, addressing the primary liver condition can improve the prognosis if the underlying liver disease is treatable or reversible.
Clinical History
Patients may have a history of underlying liver disease or symptoms related to liver dysfunction. This can include fatigue, jaundice, abdominal pain or discomfort, hepatomegaly, or ascites. A range of neuropsychiatric symptoms characterizes PSE. Patients may report changes in behavior, personality, cognition, and mood. They may experience confusion, disorientation, memory problems, difficulty concentrating, and alterations in sleep patterns.
Patients may exhibit motor abnormalities such as tremors, abnormal movements, or even coma in more severe cases. Patients may describe episodes of acute neurological deterioration, known as encephalopathy episodes. Various factors, such as infections, gastrointestinal bleeding, certain medications, dietary factors, or electrolyte imbalances, can trigger these episodes. The frequency, severity, and triggers of these episodes should be assessed.
The patient’s current and past medications should be reviewed, as certain medications can worsen or precipitate encephalopathy. Additionally, the patient’s dietary habits, particularly protein intake, should be assessed, as dietary protein can influence ammonia levels and encephalopathy severity. In some cases, a family history of liver disease or metabolic disorders may contribute to PSE. Gathering information about family members with similar conditions or neurological symptoms can provide valuable insights.
Physical Examination
The patient may exhibit varying confusion, disorientation, or impaired consciousness. In severe cases, they may be unresponsive or in a comatose state. Patients may demonstrate tremors, asterixis (flapping tremor of the hands), or other involuntary movements.
Increased muscle tone or rigidity may be observed, particularly in more advanced stages of encephalopathy. Patients may have difficulty with coordination and exhibit unsteady or ataxic gait.
A distinctive musty, sweet, or slightly fecal odor of the breath is associated with liver disease. Patients may exhibit signs of malnutrition, such as muscle wasting or loss of subcutaneous fat.
Differential Diagnoses
Meningitis
Hypoglycemia
Anoxia
Wernicke encephalopathy
Patients who experience upper gastrointestinal bleeding are at significant risk of developing hepatic encephalopathy. However, this risk can be reduced through gastrointestinal lavage using mannitol or non-absorbable disaccharides, which help decrease the likelihood of overt HE. Treating the underlying cirrhosis in a way that slows down or reverses its progression can also serve as primary prophylaxis for HE.
This can involve interventions such as alcohol abstinence for individuals with alcohol misuse, antiviral medications for virus-related cirrhosis, and appropriate nutrition for malnourished patients, addressing both excess and deficiency and iron overload, among other factors. For patients who have experienced episodes of hepatic encephalopathy and are at a higher risk of recurrence, using lactulose can reduce the risk of another episode by 50%. In cases where lactulose is not well-tolerated, rifaximin, a non-absorbable antibiotic, can be used as an alternative.
A combination of lactulose and rifaximin for patients with recurrent episodes can further decrease the risk of subsequent episodes. In cases where patients are severely debilitated due to their condition, the goal is to identify and close off the shunt causing the encephalopathy. Patients at an increased risk of aspiration or respiratory compromise should be closely monitored and may require prophylactic intubation, with intensive care unit admission as necessary.
Loading...
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
